Imaging Agent for Cardiac MRI

The new agent provides a way to simplify the diagnostic pathway for evaluating heart disease and replaces multiple tests with a single, noninvasive, cost-effective procedure, says the agent's developer, Eagle Vision Pharmaceutical Corp. (Chester Springs, PA, USA). Eagle Vision believes MRI enhanced with EVP 1001-1 will distinguish areas of the heart that are receiving inadequate blood supply with unique sensitivity, providing high resolution, 3-D images that define which of these areas are likely to benefit from treatment and which will not. The company has announced receipt of a grant (SBIR Phase 2) from the Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH) to support advanced studies of the agent, called EVP 1001-1.

"We are pleased with the continued support of our programs by the NIH that validates the potential of our proprietary technology to make a difference in people's lives,” said Dr. Peter Seoane, vice president of R&D. EVP 1001-1 will be the focus of a presentation at the annual meeting of the International Society for Magnetic Resonance in Medicine, in Scotland.